Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Aza-TdCyd |
Synonyms | |
Therapy Description |
Aza-TdCyd is a nucleoside analog that is incorporated into DNA, resulting in decreased DNMT1 and potentially leading to decreased tumor growth (Mol Cancer Ther January 1 2018 (17) (1 Supplement) LB-B12). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Aza-TdCyd | 5-Aza-4'-thio-2'-deoxycytidine|5-Aza-4-thio-2-deoxycytidine|5-Aza-TdCyd | Aza-TdCyd is a nucleoside analog that is incorporated into DNA, resulting in decreased DNMT1 and potentially leading to decreased tumor growth (Mol Cancer Ther January 1 2018 (17) (1 Supplement) LB-B12). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03366116 | Phase I | Aza-TdCyd | 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors | Recruiting | USA | 0 |